Plasma prevalence of anti-N-methyl-d-aspartate receptor IgG antibodies in early stages of psychosis
- Resource Type
- Authors
- Camila Marcelino Loureiro; Fabiana Corsi-Zuelli; Helene Aparecida Fachim; Rosana Shuhama; Natália Mota de Souza Chagas; Paulo Rossi Menezes; Cristina Marta Del-Ben; Paulo Louzada-Junior
- Source
- Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Ciência & Saúde Coletiva v.26 n.3 2021
Ciência & Saúde Coletiva
Associação Brasileira de Saúde Coletiva (ABRASCO)
instacron:ABRASCO
Ciência & Saúde Coletiva, Vol 26, Iss 3, Pp 1085-1094 (2021)
- Subject
- Male
Psychosis
medicine.medical_specialty
Bipolar Disorder
Bipolar disorder
Population
Psychotic depression
TRANSTORNOS PSICÓTICOS
Gastroenterology
Receptors, N-Methyl-D-Aspartate
Internal medicine
mental disorders
medicine
Prevalence
Humans
education
education.field_of_study
biology
business.industry
Antibodies anti-NMDAR
Health Policy
Public Health, Environmental and Occupational Health
medicine.disease
First-episode psychosis
Exact test
Psychotic Disorders
Schizophrenia
biology.protein
Female
Differential diagnosis
Analysis of variance
Public aspects of medicine
RA1-1270
Antibody
business
- Language
We investigated the feasibility of including plasma anti-NMDAR antibody screening in the assessment of first-episode psychosis patients in an early intervention programme in the Southern hemisphere. Anti-NMDAR IgG antibodies were assessed by ELISA in 166 patients (64.0% men), 166 matched population-based controls and 76 patients’ siblings (30.3% men). Fisher’s exact test and ANOVA were performed. Positive anti-NMDAR antibody patients were more often observed in bipolar disorder (10.0%) than schizophrenia (2.4%) or psychotic depression (3.1%), although no significant differences were observed. Our results are not conclusive regarding the inclusion of plasma anti-NMDAR IgG antibodies in differential diagnostic protocols for psychosis.